Johnson & Johnson Stock Rises on FDA Clearance for OTTAVA Surgical Robot

Shares of Johnson & Johnson (NYSE: JNJ) advanced in morning trading after the U.S. Food and Drug Administration (FDA) cleared its new robotic surgical system for commercial use. The authorization marks a key strategic entry for J&J's MedTech division into the soft-tissue robotics market, a segment long dominated by Intuitive Surgical.

FDA Greenlights OTTAVA System

The FDA granted De Novo authorization for the OTTAVA Robotic Surgical System, clearing it for use in a range of general surgery procedures in the upper abdomen. According to the company, these include gastric bypass, cholecystectomy, appendectomy, and hernia repair. The clearance follows the submission of data from a clinical study in January 2026.

Johnson & Johnson highlighted the system's table-integrated design, which it states occupies 30% to 50% less space in an operating room compared to traditional cart-based robotic systems. This feature could appeal to hospitals looking to optimize surgical capacity without significant infrastructure investment.

Market Impact and Competitive Landscape

The regulatory approval provided a direct catalyst for the company's stock, which rose 1.1% in morning trading, outperforming a mixed broader market. The development is significant for investors as it positions J&J as a direct competitor to Intuitive Surgical, whose da Vinci systems have been the standard in robotic-assisted surgery for over two decades.

The stock's positive move appeared to be a company-specific reaction, as the Dow Jones Industrial Average was up only modestly while the S&P 500 was nearly flat. The advance continues J&J's recovery from its 52-week low of $164.23.

Ad

Building on Earnings Momentum

The positive news on OTTAVA builds on a foundation of recent fundamental strength. On July 15, Johnson & Johnson reported strong second-quarter 2026 earnings that surpassed analyst expectations.

Key figures from the Q2 report include:

• Worldwide sales of $25.3 billion, an increase of 6.6% year-over-year.
• Adjusted earnings per share (EPS) of $2.90, beating the consensus estimate of $2.85.

Following the report, management raised its full-year guidance for both sales and adjusted EPS, signaling confidence in its Innovative Medicine and MedTech businesses. The combination of a strong earnings report and a major new product clearance has reinforced investor conviction in the company's growth outlook.